Direct labelling of the human P2X7receptor and identification of positive and negative cooperativity of binding
- 1 May 2007
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 151 (1) , 84-95
- https://doi.org/10.1038/sj.bjp.0707196
Abstract
Background and Purpose: The P2X7receptor exhibits complex pharmacological properties. In this study, binding of a [3H]‐labelled P2X7receptor antagonist to human P2X7receptors has been examined to further understand ligand interactions with this receptor.Experimental Approach: The P2X7receptor antagonist,N‐[2‐({2‐[(2‐hydroxyethyl)amino]ethyl}amino)‐5‐quinolinyl]‐2‐tricyclo[3.3.1.13,7]dec‐1‐ylacetamide (compound‐17), was radiolabelled with tritium and binding studies were performed using membranes prepared from U‐2 OS or HEK293 cells expressing human recombinant P2X7receptors.Key Results: Binding of [3H]‐compound‐17 was higher in membranes prepared from cells expressing P2X7receptors than from control cells and was inhibited by ATP suggesting labelled sites represented human P2X7receptors. Binding was reversible, saturable and modulated by P2X7receptor ligands (Brilliant Blue G, KN62, ATP, decavanadate). Furthermore, ATP potency was reduced in the presence of divalent cations or NaCl. Radioligand binding exhibited both positive and negative cooperativity. Positive cooperativity was evident from bell shaped Scatchard plots, reduction in radioligand dissociation rate by unlabelled compound‐17 and enhancement of radioligand binding by KN62 and unlabelled compound‐17. ATP and decavanadate inhibited binding in a negative cooperative manner as they enhanced radioligand dissociation.Conclusions: These data demonstrate that human P2X7receptors can be directly labelled and provide novel insights into receptor function. The positive cooperativity observed suggests that binding of compound‐17 to one subunit in the P2X7receptor complex enhances subsequent binding to other P2X7subunits in the same complex. The negative cooperative effects of ATP suggest that ATP and compound‐17 bind at separate, interacting, sites on the P2X7receptor.British Journal of Pharmacology(2007)151, 84–95. doi:10.1038/sj.bjp.0707196Keywords
This publication has 42 references indexed in Scilit:
- Species and response dependent differences in the effects of MAPK inhibitors on P2X7receptor functionBritish Journal of Pharmacology, 2006
- Dimer-based model for heptaspanning membrane receptorsTrends in Biochemical Sciences, 2005
- Atomic Force Microscopy Imaging Demonstrates that P2X2 Receptors Are Trimers but That P2X6 Receptor Subunits Do Not OligomerizeJournal of Biological Chemistry, 2005
- Recent progress in the discovery of antagonists acting at P2X7receptorExpert Opinion on Therapeutic Patents, 2005
- Trimeric Architecture of Homomeric P2X2 and Heteromeric P2X1+2 Receptor SubtypesJournal of Molecular Biology, 2004
- Heterologous Expression of G Protein?Coupled Receptors in U-2 OS Osteosarcoma CellsReceptors and Channels, 2004
- Recombinant Baculoviruses Used to Study Estrogen Receptor Function in Human Osteosarcoma CellsASSAY and Drug Development Technologies, 2003
- Effects of antagonists at the human recombinant P2X7 receptorBritish Journal of Pharmacology, 1998
- The isoquinoline derivative KN‐62 a potent antagonist of the P2Z‐receptor of human lymphocytesBritish Journal of Pharmacology, 1997
- The Cytolytic P 2Z Receptor for Extracellular ATP Identified as a P 2X Receptor (P2X 7 )Science, 1996